About Us | Contact

Dr. Brian Ross Zeno Investigator

Riverside Methodist Hospital NPI1033149596
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$160,092.91
from 31 payments in the last 6 years

Total Cash or Cash Equivalent

$159,968.51
from 30 payments in the last 6 years

Total In-kind Items & Services

$124.40
from 1 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
10/26/2021 General (Non-Research) In-kind items and services Food and Beverage $124.40 Details
Payment from Ethicon Inc.
Payment Record ID 787630605
09/29/2020 Research Cash or cash equivalent $66822.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS
Clinical Trials Gov ID NCT04427501
Payment Record ID 728718011
06/21/2018 Research Cash or cash equivalent $962.50 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Payment Record ID 606975309
04/24/2018 Research Cash or cash equivalent $1358.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Payment Record ID 606974291
05/07/2018 Research Cash or cash equivalent Drug $15750.00 Details
Payment from Lupin Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS
Payment Record ID 605054509
04/03/2018 Research Cash or cash equivalent Drug $190.00 Details
Payment from Lupin Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS
Payment Record ID 605054505
03/20/2018 Research Cash or cash equivalent Drug $5000.00 Details
Payment from Lupin Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS
Payment Record ID 605054501
03/12/2018 Research Cash or cash equivalent Drug $870.00 Details
Payment from Lupin Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS
Payment Record ID 605054497
03/05/2018 Research Cash or cash equivalent Drug $4737.60 Details
Payment from Lupin Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS
Payment Record ID 605054493
02/20/2018 Research Cash or cash equivalent Drug $1930.00 Details
Payment from Lupin Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS
Payment Record ID 605054488
02/05/2018 Research Cash or cash equivalent Drug $1945.00 Details
Payment from Lupin Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS
Payment Record ID 605054483
02/05/2018 Research Cash or cash equivalent Drug $8205.30 Details
Payment from Lupin Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS
Payment Record ID 605054479
01/22/2018 Research Cash or cash equivalent Drug $2589.35 Details
Payment from Lupin Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS
Payment Record ID 605054474
01/22/2018 Research Cash or cash equivalent Drug $4129.33 Details
Payment from Lupin Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS
Payment Record ID 605054469
01/16/2018 Research Cash or cash equivalent Drug $2298.00 Details
Payment from Lupin Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS
Payment Record ID 605054465
01/16/2018 Research Cash or cash equivalent Drug $3845.00 Details
Payment from Lupin Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS
Payment Record ID 605054463
01/08/2018 Research Cash or cash equivalent Drug $29848.50 Details
Payment from Lupin Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS
Payment Record ID 605054459
05/25/2017 Research Cash or cash equivalent $3000.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study GSP304-201
Payment Record ID 494595647
10/26/2017 Research Cash or cash equivalent $2088.45 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study GSP304-201
Payment Record ID 494595639
07/06/2017 Research Cash or cash equivalent $1358.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study GSP304-201
Payment Record ID 494595637
07/06/2017 Research Cash or cash equivalent $1237.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study GSP304-201
Payment Record ID 494595629
09/21/2017 Research Cash or cash equivalent $522.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study GSP304-201
Payment Record ID 494595623
04/27/2017 Research Cash or cash equivalent $500.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study GSP304-201
Payment Record ID 494595617
07/06/2017 Research Cash or cash equivalent $438.15 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study GSP304-201
Payment Record ID 494595611
11/09/2017 Research Cash or cash equivalent $232.05 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study GSP304-201
Payment Record ID 494595604
04/27/2017 Research Cash or cash equivalent $37.02 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study GSP304-201
Payment Record ID 494595598
07/27/2017 Research Cash or cash equivalent $30.76 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study GSP304-201
Payment Record ID 494595589
04/27/2017 Research Cash or cash equivalent $19.06 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study GSP304-201
Payment Record ID 494595585
04/27/2017 Research Cash or cash equivalent $17.98 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study GSP304-201
Payment Record ID 494595579
04/27/2017 Research Cash or cash equivalent $7.06 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study GSP304-201
Payment Record ID 494595573
04/27/2017 Research Cash or cash equivalent $0.40 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study GSP304-201
Payment Record ID 494595567
;